TY - JOUR T1 - Outcomes and regional differences in practice in a worldwide coronary stent registry JF - Heart JO - Heart DO - 10.1136/heartjnl-2021-320116 SP - heartjnl-2021-320116 AU - Murat Cimci AU - Jawed Polad AU - Mamas Mamas AU - Andres Iniguez-Romo AU - Bernard Chevalier AU - Rajpal Abhaichand AU - Adel Aminian AU - Ariel Roguin AU - Gabriel Maluenda AU - Michael Angioi AU - Graham Cassel AU - Shoichi Kuramitsu AU - Lotte Jacobs AU - Roxane Debrus AU - Fazila Malik AU - David Hildick-Smith AU - Peep Laanmets AU - Marco Roffi A2 - , Y1 - 2022/01/09 UR - http://heart.bmj.com/content/early/2022/01/20/heartjnl-2021-320116.abstract N2 - Objective The primary objective was to assess the performance of a new generation thin-strut sirolimus-eluting coronary stent with abluminal biodegradable polymer in an all comer population. The secondary objective was to detail differences in contemporary percutaneous coronary intervention (PCI) practice worldwide.Methods e-Ultimaster was an all-comer, prospective, global registry (NCT02188355) with independent event adjudication enrolling patients undergoing PCI with the study stent. The primary outcome measure was target lesion failure (TLF) at 1 year, defined as the composite of cardiac death, target vessel myocardial infarction and clinically driven target lesion revascularisation. Data were stratified according to 4 geographical regions.Results A total of 37 198 patients were enrolled (Europe 69.2%, Asia 17.8%, Africa/Middle East 6.6% and South America/Mexico 6.5%) and 1-year follow-up was available for 35 389 patients (95.1%). One-year TLF occurred in 3.2% of the patients, ranging from 2% (Africa/Middle East) to 4.1% (South America/Mexico). In patients with acute coronary syndrome, potent P2Y12 inhibitors were prescribed in 48% of patients at discharge, while at 1 year 72% were on any dual antiplatelet therapy. Lipid-lowering treatment was administered in 80.9% and 75.5% of patients at discharge and 1 year, respectively. Regional differences in the profile of the treated patients as well as in PCI practice were reported.Conclusions In this investigation with worldwide representation, contemporary PCI using a new generation thin-strut sirolimus-eluting coronary stent with abluminal biodegradable polymer was associated with low 1-year TLF across clinical presentations and continents. Suboptimal adherence to current recommendations around antiplatelet and lipid lowering treatments was detected.Data are available on reasonable request. Data also uploaded as online supplemental material. ER -